Literature DB >> 16906454

Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.

Karl Brendel1, Emmanuelle Comets, Céline Laffont, Christian Laveille, France Mentré.   

Abstract

PURPOSE: The aim of this study is to define and illustrate metrics for the external evaluation of a population model.
MATERIALS AND METHODS: In this paper, several types of metrics are defined: based on observations (standardized prediction error with or without simulation and normalized prediction distribution error); based on hyperparameters (with or without simulation); based on the likelihood of the model. All the metrics described above are applied to evaluate a model built from two phase II studies of gliclazide. A real phase I dataset and two datasets simulated with the real dataset design are used as external validation datasets to show and compare how metrics are able to detect and explain potential adequacies or inadequacies of the model.
RESULTS: Normalized prediction errors calculated without any approximation, and metrics based on hyperparameters or on objective function have good theoretical properties to be used for external model evaluation and showed satisfactory behaviour in the simulation study.
CONCLUSIONS: For external model evaluation, prediction distribution errors are recommended when the aim is to use the model to simulate data. Metrics through hyperparameters should be preferred when the aim is to compare two populations and metrics based on the objective function are useful during the model building process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16906454      PMCID: PMC2124466          DOI: 10.1007/s11095-006-9067-5

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  21 in total

Review 1.  Pharmacokinetic/pharmacodynamic modeling in drug development.

Authors:  L B Sheiner; J L Steimer
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

2.  Evaluation of tests based on individual versus population modeling to compare dissolution curves.

Authors:  E Comets; F Mentré
Journal:  J Biopharm Stat       Date:  2001       Impact factor: 1.051

3.  Ways to fit a PK model with some data below the quantification limit.

Authors:  S L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

4.  Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.

Authors:  N Frey; C Laveille; M Paraire; M Francillard; N H G Holford; Roeline Jochemsen
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

5.  Prediction discrepancies for the evaluation of nonlinear mixed-effects models.

Authors:  France Mentré; Sylvie Escolano
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-13       Impact factor: 2.745

6.  Performance of Bayesian feedback to forecast lidocaine serum concentration: evaluation of the prediction error and the prediction interval.

Authors:  S Vozeh; T Uematsu; G F Hauf; F Follath
Journal:  J Pharmacokinet Biopharm       Date:  1985-04

7.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

8.  Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers.

Authors:  P Delrat; M Paraire; R Jochemsen
Journal:  Biopharm Drug Dispos       Date:  2002-05       Impact factor: 1.627

9.  Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.

Authors:  Y Yano; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

10.  Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients.

Authors:  Emmanuelle Comets; Kazumasa Ikeda; Paulo Hoff; Pierre Fumoleau; Jantien Wanders; Yusuke Tanigawara
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-08       Impact factor: 2.745

View more
  144 in total

1.  Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects.

Authors:  Nageshwar R Budha; Andreas Kovar; Bernd Meibohm
Journal:  AAPS J       Date:  2011-10-18       Impact factor: 4.009

2.  Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.

Authors:  Jürgen B Bulitta; Martina Kinzig; Verena Jakob; Ulrike Holzgrabe; Fritz Sörgel; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

3.  Scaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models.

Authors:  Massimo Cella; Catherijne Knibbe; Saskia N de Wildt; Joop Van Gerven; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

4.  Visual Predictive Check in Models with Time-Varying Input Function.

Authors:  Anna Largajolli; Alessandra Bertoldo; Marco Campioni; Claudio Cobelli
Journal:  AAPS J       Date:  2015-08-12       Impact factor: 4.009

5.  Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults.

Authors:  Caroline Petit; Vincent Jullien; Adeline Samson; Jérémie Guedj; Jean-René Kiechel; Sarah Zohar; Emmanuelle Comets
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

6.  Population Pharmacokinetics and Dosing Optimization of Imipenem in Children with Hematological Malignancies.

Authors:  Lei Dong; Xiao-Ying Zhai; Yi-Lei Yang; Li Wang; Yue Zhou; Hai-Yan Shi; Bo-Hao Tang; Yue-E Wu; Fan Yang; Li Wen; Hong-Xiao Kong; Li-Juan Zhi; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 7.  Covariate pharmacokinetic model building in oncology and its potential clinical relevance.

Authors:  Markus Joerger
Journal:  AAPS J       Date:  2012-01-25       Impact factor: 4.009

8.  Amikacin maturation model as a marker of renal maturation to predict glomerular filtration rate and vancomycin clearance in neonates.

Authors:  Wei Zhao; Valérie Biran; Evelyne Jacqz-Aigrain
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

Review 9.  Computational approaches to analyse and predict small molecule transport and distribution at cellular and subcellular levels.

Authors:  Kyoung Ah Min; Xinyuan Zhang; Jing-yu Yu; Gus R Rosania
Journal:  Biopharm Drug Dispos       Date:  2013-12-10       Impact factor: 1.627

10.  Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.

Authors:  Isabelle Benz-de Bretagne; Noël Zahr; Amélie Le Gouge; Jean-Sébastien Hulot; Caroline Houillier; Khe Hoang-Xuan; Emmanuel Gyan; Séverine Lissandre; Sylvain Choquet; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.